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Downregulated Wnt/β-catenin 
signalling in the Down syndrome 
hippocampus
simone Granno  1,2, Jonathon Nixon-Abell1,3, Daniel C. Berwick1,4, Justin tosh2, 
George Heaton1, Sultan Almudimeegh1, Zenisha Nagda1, Jean-Christophe Rain5, 
Manuela Zanda6, Vincent plagnol  6, Victor L. J. tybulewicz  7,8,9, Karen Cleverley2, 
Frances K. Wiseman2,9, Elizabeth M. C. Fisher2,9 & Kirsten Harvey1
Pathological mechanisms underlying Down syndrome (DS)/Trisomy 21, including dysregulation of 
essential signalling processes remain poorly understood. Combining bioinformatics with RNA and 
protein analysis, we identified downregulation of the Wnt/β-catenin pathway in the hippocampus of 
adult DS individuals with Alzheimer’s disease and the ‘Tc1’ DS mouse model. Providing a potential 
underlying molecular pathway, we demonstrate that the chromosome 21 kinase DYRK1A regulates 
Wnt signalling via a novel bimodal mechanism. Under basal conditions, DYRK1A is a negative regulator 
of Wnt/β-catenin. Following pathway activation, however, DYRK1A exerts the opposite effect, 
increasing signalling activity. In summary, we identified downregulation of hippocampal Wnt/β-catenin 
signalling in DS, possibly mediated by a dose dependent effect of the chromosome 21-encoded kinase 
DYRK1A. Overall, we propose that dosage imbalance of the Hsa21 gene DYRK1A affects downstream 
Wnt target genes. Therefore, modulation of Wnt signalling may open unexplored avenues for DS and 
Alzheimer’s disease treatment.
Down syndrome (DS) is the most common human aneuploidy, occurring in approximately 1/700–1000 live 
births1. It is caused by trisomy of chromosome 21 (Hsa21) and is associated with several distinctive character-
istics, including intellectual disability and neurodegeneration2–6. DS phenotypes likely arise from gene dosage 
effects resulting from the additional chromosome7,8. However, the key cellular mechanisms underlying pathology 
are poorly understood. Identification of target molecular pathways contributing to the disease is urgently needed 
to develop effective therapeutic strategies. In this study, we investigated dysfunction of canonical Wnt/β-catenin 
signalling in DS. The Wnt signalling pathway is a highly conserved signal transduction cascade with high activity 
during development but of key importance in adulthood as well9. Activation of the pathway is dependent upon 
nuclear translocation of β-catenin, which drives expression of several target genes. Canonical Wnt signalling 
plays fundamental, well-described roles in several biological processes, including development10,11, adult nervous 
system function12, stem cell function13 and tumorigenesis14.
DS has long been associated with a high incidence of early-onset Alzheimer’s disease (AD-DS)15–17. On the 
other hand, recent evidence has consistently implicated defects in canonical Wnt signalling in the pathogenesis 
of AD18–24. Here, we identified substantial Wnt signalling downregulation in the hippocampus of DS individuals 
with AD pathology and the Tc1 mouse model of DS. This suggests the presence of a novel functional relationship 
between DS and Wnt signalling, which may contribute to the development of AD in the ageing DS population. 
We further characterised such relationship via a candidate gene approach. Wnt dysregulation in DS, in fact, 
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might arise from increased expression of key Hsa21-encoded proteins such as DYRK1A (dual-specificity tyros-
ine phosphorylation-regulated kinase 1A). In support of this hypothesis, we present evidence of novel bimodal 
regulatory effects of DYRK1A overexpression, kinase inhibition and interaction with other Wnt signalling com-
ponents. The kinase DYRK1A has a multitude of substrates regulating developmental, neuronal and neurode-
generative cell signalling mechanisms, and functionally interacts with the primary Wnt components GSK3β and 
p120/δ-catenin25–36. DYRK1A is thought to be an essential mediator of intellectual disability in DS, and has also 
been proposed to contribute to DS/AD pathogenesis as well as idiopathic AD37–45.
Results
Wnt signalling is downregulated in human AD-DS. We first sought to determine whether canonical 
Wnt signalling alterations are present in the human DS hippocampus. Employing immunoblotting, we character-
ised activity of the Wnt pathway in post mortem human hippocampal samples from DS adults (Newcastle Brain 
Bank, average age at death: 56 years; Fig. 1A). Available clinical information indicated the presence of dementia 
in all patients, with a majority displaying AD neuropathology, typical of DS at this age of death, as assessed by 
Braak staging (Table S1).
The Hsa21-encoded protein DYRK1A was selected as a marker of Hsa21 trisomy, given its ubiquitous upreg-
ulation and key importance in DS27. As expected, DYRK1A protein levels were elevated in human hippocampal 
samples (Fig. 1B, red). In order to biochemically quantify Wnt signalling activity levels, we measured protein 
amounts of ‘free’ β-catenin, represented by its dephosphorylated form at Ser37/Thr41 and expressed as a fraction 
of total β-catenin. This is a well established approach46. Strikingly, we observed a substantial decrease in hip-
pocampal active β-catenin (~3-fold, P = 0.003; Fig. 1C, left blue), whilst levels of total β-catenin remained unaf-
fected. We also detected a significant decrease in hippocampal protein levels of the Wnt inhibitor DKK3 (Fig. 1C, 
right blue). Total amounts of the key β-catenin inhibitor GSKβ showed no significant differences. Post-mortem 
human data thus demonstrated suppressed Wnt signalling activity in the DS hippocampus, a novel finding impli-
cating this pathway in DS pathology.
Wnt signalling is downregulated in the Tc1 mouse hippocampus. Having newly identified 
Wnt signalling downregulation in the human DS hippocampus, we expanded our analysis to the Tc1 mouse, 
an established DS model47, in order to validate this finding. To this end, we performed a combined analysis 
at the transcriptomic and protein levels. We first employed RNA sequencing (RNAseq) to investigate differen-
tial gene expression in the Tc1 hippocampus (Figs 2 and 3; n = 3, males, 3 months)47. The Tc1 mouse carries a 
freely-segregating, near-complete Hsa21 (70%, Fig. 3A). In accordance with previous reports, RNAseq analysis 
indicated that, in this model, not all triplicated genes are dosage-sensitive (Fig. 2A,B) and are thus not equally 
likely to contribute to phenotypes47–49. Additionally, genome-wide transcriptional alterations were observed 
beyond Hsa21, with 64 differentially expressed (DEX) Tc1 genes (Fig. 2C and Table S2, P < 0.05). This known 
phenomenon50 circumstantially suggests that Hsa21 trisomy might affect molecular pathways regulating global 
gene expression, such as canonical Wnt signalling.
Given our findings in human hippocampi, as well as the known roles of Wnt signalling in several biolog-
ical mechanisms likely to be important in DS, such as brain development and AD, we employed QIAGEN 
Ingenuity® Pathway Analysis (IPA)51 to search the DEX gene dataset for Wnt signalling abnormalities. Hsa21 
genes were excluded from the analysis, in order to isolate secondary transcriptional effects mediated by trisomy, 
but not directly associated with overexpression of triplicated genes. In the Tc1 hippocampus, pathway analysis 
(Fig. 3B) revealed a significant association with canonical Wnt signalling (P = 0.00173), with four corresponding 
DEX genes directly linked to the pathway (Fig. 3C, red circles; Axin2, Cdd4, Cdh1, Dkk3). We then performed 
upstream analysis, probing the IPA knowledge base for regulators potentially responsible for observed expression 
patterns. This approach detected a further 15 Tc1 DEX genes as significantly regulated by Wnt proteins (Fig. 3C). 
Interestingly, virtually all Wnt signalling components were identified as significant upstream regulators (Fig. 3D, 
left panel; Table S3). This finding suggests a high degree of overlap between the Tc1 hippocampal transcriptome 
and Wnt signalling function, given that IPA linked all essential Wnt signalling components to one or more DEX 
genes. The transcriptional activator β-catenin (Fig. 3C, dotted circles) and the ligand Wnt3a (squares) were most 
significantly associated with hippocampal Tc1 expression patterns, regulating expression of 11 and 6 DEX genes, 
respectively (P < 0.0001). Additionally, IPA-generated activation z-scores were overall predictive of significant 
downregulation of Wnt activity, with negative values registered for several regulators, including β-catenin and 
Wnt3a (Fig. 3D, right panel). Importantly, these results are consistent with our biochemical data in humans.
Next, we employed immunoblotting to investigate levels of Wnt signalling activity in the Tc1 mouse hip-
pocampus (n = 8, 6 months of age; Fig. 3E). The Hsa21-encoded protein DYRK1A was once again selected as a 
marker of Hsa21 trisomy, based on RNAseq results for duplicated genes (Fig. 2A,B) and its importance in DS27. 
As expected, we found DYRK1A protein levels to be elevated in the Tc1 hippocampus (Fig. 3E, red). In line with 
human DS hippocampal data, the active β-catenin fraction was significantly reduced ~3-fold (Fig. 3E, blue), 
whilst total β-catenin remained unaltered. These results were also consistent with IPA predictions, overall sug-
gesting substantial Wnt signalling downregulation in the adult Tc1 mouse hippocampus.
We then assessed Tc1 hippocampal expression of the Wnt inhibitor Dkk3 and target gene Axin2, shown by 
RNAseq to be up- and downregulated in the Tc1 mouse, respectively. By quantitative PCR (qPCR, Fig. 3F), we 
found levels consistent with RNAseq data: Dkk3 expression was significantly elevated, while Axin2 trended 
toward decrease (P = 0.0571). Consistently, DKK3 protein levels were elevated in the Tc1 hippocampus (Fig. 3G, 
red). This finding, however, was directionally opposite to what we observed in the human DS hippocampus, 
where DKK3 protein levels were decreased. We then quantified GSK3β, finding no differences in protein lev-
els (Fig. 3G). The serine 9 (Ser9)-phosphorylated form of GSK3β, expressed as a fraction of total GSK3β was 
also unaltered, as previously shown in young Tc1 mouse brains52,53. Phosphorylation of this residue is however 
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reportedly elevated in aged (20 months) Tc1 hippocampal and cerebral cortical tissue, suggesting a potential 
age-related effect.
We also probed for total and active β-catenin in the hippocampus of two additional DS models the Dp(10)1Yey 
and Dp(17)1Yey54. These are segmentally trisomic for Mmu10/17 regions of synteny with Hsa21 (Fig. 3A). In 
Figure 1. Wnt signalling is altered in human DS. (A) Overview of human DS brain samples employed in 
immunoblot analysis, indicating no significant difference in age of death and post-mortem delay of sample 
collection between DS and euploid controls. (B,C) Immunoblot analysis of the human DS hippocampus (n = 8) 
demonstrating significantly elevated DYRK1A levels (red), as expected, with substantially reduced active 
β-catenin fraction (blue). DKK3 levels were also significantly reduced (blue).
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Figure 2. Overview of hippocampal RNAseq in the Tc1 mouse model of DS. (A) Hsa21 genes in the Tc1 
mouse hippocampus (n = 3, adjusted P < 0.05), as detected by RNAseq. Overall expression levels of 180 
Hsa21 genes which could reliably measured by RNAseq are visually summarised. Of these, 143 could be tested 
for significance (others highlighted by black circle). Genes are presented alphabetically and colour-coded 
according to log2 fold change/WT. Gene set is matched against a reference list 224 of Hsa21-Tc1 genes published 
by Gribble et al.48, providing an overview of expected deletions/duplications (undetected genes present in 
reference list are crossed out). Copy number refers to Hsa21 genes, with ‘one copy’ indicating modelled 
triplication of the relevant gene (1 human + 2 endogenous mouse copies). (B) Expression levels plotted as 
a function of significance, highlighting DS/AD-relevant genes, and demonstrating the presence of several 
genes not functionally overexpressed (blue), including APP. (C) Expression levels of 64 Tc1 DEX genes (n = 3, 
adjusted P < 0.05) beyond Hsa21, arranged by chromosomal number, indicating occurrence of genome-wide, 
bidirectional transcriptional alterations.
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these tissues, we found no significant alterations in Wnt activity (Fig. S2). Overall, RNAseq analysis and immu-
noblotting results were consistent, suggesting significant downregulation of Wnt signalling activity in the Tc1 
mouse hippocampus. Since we saw no effects on Wnt signalling in mice carrying triplications of Mmu10 or 17, 
this novel Tc1 phenotype likely arises from gene(s) with homology to Mmu16.
Our data overall suggest novel Wnt/β-catenin signalling dysfunction in DS, with consistent downregulation 
observed in both human and Tc1 hippocampi. At this stage, however, we cannot exclude that directional changes 
may be variable, and tissue-specific.
DYRK1A interacts with Wnt signalling components. Given these results, we hypothesised that one 
or more of the Hsa21 genes that are differentially expressed in DS mediated the detected alterations in canonical 
Wnt signalling. The absence of Wnt signalling changes in the Dp(10)1Yey and Dp(17)1Yey mouse models sug-
gests that Mmu10/17 regions of synteny with Hsa21 are unlikely to influence the phenotypes observed in the Tc1 
Figure 3. Genetic and biochemical analysis of the Tc1 hippocampus reveals abnormalities in canonical Wnt 
signalling. (A) Overview of DS mouse models employed derived from50, highlighting Hsa21 syntenic regions on 
mouse chromosomes 10, 16 and 17 (left, syntenic gene number in brackets) and trisomic regions in the Tc147,48, 
Dp(17)1Yey and Dp(17)1Yey (54) strains (right, duplicated gene number in brackets). (B) Pathway analysis of 
the Tc1 dataset. (C) Curated list of differentially expressed (DEX), Wnt-related genes for individual Tc1 mice 
as measured via RNAseq (RNAseq) (n = 3; 3 months; adjusted P < 0.05). Genes included were identified by 
Qiagen IPA as either primary Wnt signalling components (red circles) or as regulated by β-catenin (blue dotted 
circles). Values are expressed as log2fold changes. (D) IPA Upstream analysis of the Tc1 dataset, revealing several 
canonical Wnt components as regulators of DEX genes (left panel). Predictive activation z-scores calculated 
by IPA for upstream regulators with sufficient overlap (right panel) plotting scores as a function of significance 
(−log10P). (E) Immunoblot analysis of male Tc1 mouse hippocampi (n = 8, 160 ± 28 days) compared to age-
matched littermates demonstrated enhanced levels of DYRK1A, as expected (red), with reduced canonical 
Wnt signalling activity (blue). Signal represents the ratio of Ser37/Thr41 dephosphorylated β-catenin to total 
amounts of β-catenin. (F) Quantitative real-time PCR (qPCR) of DKK3 and AXIN2, two DEX Wnt components 
in the Tc1 hippocampus, demonstrating significantly elevated DKK3 expression (red), and a decreased AXIN2 
levels (blue). (G) Immunoblot analysis of Tc1 hippocampal samples (n = 8) revealed unaltered levels of total and 
p-Ser9 GSK3β as previously described52,53 and enhanced DKK3 protein levels (red).
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hippocampus. Thus, candidate Wnt modulators likely map to Mmu16. A number of Hsa21 genes may affect Wnt 
signalling31,55–57, including amyloid precursor protein (APP) and DYRK1A, which might be particularly impor-
tant given their roles in DS and AD27,50. However, because of the lack of functional APP overexpression in the 
Tc1 mouse48 (Fig. 2A,B), this gene is unlikely to primarily mediate hippocampal Wnt phenotypes in this model. 
Therefore, we selected DYRK1A for further study, though we do not exclude that APP and/or other Hsa21 genes 
may also affect Wnt signalling.
To investigate DYRK1A as a candidate Wnt signalling modulator, we assessed whether this protein was able to 
physically interact with components of the cascade. We first probed the entire DYRK family of genes (DYRK1A/B, 
DYRK2-4) for association with the Wnt pathway (Fig. S3), employing the STRING protein interaction database, 
v10.058. For all DYRK family members, a significant association was detected with the gene ontology (GO) and 
KEGG terms ‘Wnt signalling pathway’. We then consulted a database of protein-protein interaction networks in 
DS, generated via Yeast Two-hybrid (YTH) screening. We searched the database for DYRK1A interactors with 
known functional relevance to Wnt signalling. In yeast, DYRK1A interacted with the Wnt inhibitor DKK3 at 
amino acids 589–763 (Fig. S4), a sequence reportedly important for its nuclear localisation59. DYRK1A was also 
found to interact with Lipoprotein receptor-related protein (LRP) 1/1B/4, Wnt inhibitory factor 1 (WIF1), Wnt3 
and α-catenin (Summarised in Fig. 4D).
We then employed co-immunoprecipitation (coIP) in HEK293 cells validating the DYRK1A-DKK3 interac-
tion (Fig. 4A–D). We also found that DYRK1A precipitated with the key Wnt transducer disheveled-1 (DVL1), 
Figure 4. DYRK1A may participate in a highly-interconnected Wnt signalling protein interaction network.  
(A–C) Tag co-immunoprecipitation experiments verified via immunoblotting demonstrate a positive 
interaction between DYRK1A-DKK3 (A, blue) and DYRK1A-DVL1 (B, red). No direct interaction with 
β-catenin was observed, as previously described31. (C) For all co-IPs, 0.5 μg/ml of each construct was transfected 
for 24 hrs, in three independent repeats. (D) Co-immunoprecipitation of DYRK1A-DVL1 and DYRK1A-DKK3 
protein complexes in HEK293 cells under endogenous conditions. Complexes were pulled down with magnetic 
beads coupled to either a DYRK1A (lane 3) or DVL1 antibody (lane 4). Lanes 1 (mock coIP, beads only), 3 and 
4 represent results reactions identical conditions save for the antibody employed for pull-down. Lane 2 was 
loaded with whole cell lysate from the same experimental batch as input. (E) Visual summary of DYRK1A-Wnt 
protein-protein interactions identified by the Jerome LeJeune foundation interPP project (Y2H screen, double 
coloured lines), literature sources (solid black line) and experimental evidence (dotted black line). Red and blue 
lines represent differential degrees of confidence in interaction strength. Red circled proteins were selected for 
further STRING network investigation as first shell. (F) Extended DYRK1A network from proteins selected in 
(E) adding 10 direct interactors for each node and a further 10 secondary interactors, demonstrating DYRK1A 
may be closely associated with protein-protein interactions involved in Wnt signalling. Major pathway 
components such as β-catenin were automatically integrated in the network by STRING.
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but not β-catenin (Fig. 4B,C). Importantly, we consistently observed DYRK1A interactions with DVL1 and DKK3 
via overexpression (Fig. 4A–C) as well as endogenously (Fig. 4D). The latter finding suggests the physiological 
occurrence of these protein interactions. To contextualise them further, we employed the Cytοscape software to 
build a network of potentially relevant DYRK1A-Wnt interactions and pathways. We combined the most reliable 
DYRK1A partners from YTH, coIP and literature data (Fig. 4E, red circles) into a single network enriched via 
STRING (Fig. 4F). Interestingly, we found that some of the network nodes were altered in humans DS and Tc1 
mouse hippocampi, as shown in our biochemical and transcriptomic studies (Fig. 4F, blue circles). Overall these 
data suggest DYRK1A might be involved in Wnt signalling protein interaction networks, and may thus be able to 
influence Wnt function.
DYRK1A is a bimodal Wnt signalling regulator. We next determined whether DYRK1A could mod-
ulate the transcriptional activity of β-catenin in human cells. First, the effect of DYRK1A kinase inhibition on 
LiCl or Wnt3a-driven Wnt signalling activity was investigated in a neuroblastoma (SH-SY5Y) cell line stably 
expressing a Wnt signalling luciferase reporter (Fig. 5A,B). We employed three DYRK1A inhibitors, EGCG60, 
INDY61 and Harmine62, at previously published doses to achieve target-specific inhibition (25 μM EGCG/INDY, 
10 μM Harmine). Overall, DYRK1A inhibition reduced active but not basal Wnt signalling following stimulation 
with LiCl or Wnt3a (Fig. 5A,B, blue; Fig. 5D). As expected, no dose-dependence was observed for INDY effects 
on basal Wnt levels (Fig. S5), whereas the effect of INDY on active signalling was dose-dependent (Fig. 5C, red 
dotted line) within a target-specific range61. Interestingly, Wnt-activating Lithium treatment, here influenced by 
DYRK1A inhibition, has been previously found to rescue cognitive defects and synaptic plasticity in the Ts65Dn 
mouse model of DS63.
Next, we investigated whether canonical Wnt signalling activity could be affected by DYRK1A overexpres-
sion. Surprisingly given the inhibition data, we found basal activity was potently downregulated by DYRK1A 
overexpression, with a significant reduction to nearly undetectable levels (Fig. 5E, blue). However, DYRK1A 
exerted a diametrically opposite effect on active signalling, in accordance with the kinase inhibitor exper-
iments. When co-expressed with DVL1, the resulting luciferase-reported signal was enhanced approximately 
eight-fold compared to DVL1 alone (Fig. 5E, red). Given the inhibitory effect on basal signalling activity, we 
tested whether DYRK1A overexpression could affect protein levels of GSK3β, a principal intracellular inhibitor 
of active β-catenin. We identified a significant increase in total GSK3β levels (Fig. 5F, red) along with reduced 
phosphorylation of the inhibitory Ser 9 residue (pSer9, Fig. 5F, blue) in accordance with decreased canonical Wnt 
signaling activity.
In summary, increases in DYRK1A result in reduction of basal Wnt signalling activity but further increases 
active Wnt signalling substantially. The activation-dependence of the latter effect is supported by the kinase inhib-
itor data, as DYRK1A kinase inhibition reduces active Wnt signalling. In our system, however, DYRK1A kinase 
inhibition has no measurable effect on basal Wnt signalling activity. These data overall suggest the presence of 
newly identified, bimodal Wnt signalling regulation by DYRK1A.
Wnt signalling activation induces cytoplasmic redistribution of nuclear DYRK1A. Given the 
observed bimodal Wnt effects of DYRK1A, we hypothesised that the subcellular localisation of this kinase may 
be modified by Wnt activation states. A shift in distribution and availability of DYRK1A pools may account 
for its differential regulation of Wnt signalling activity. DYRK1A localises prominently to the nucleus but also 
the cytoplasm27,59,64,65. In HeLa and HEK293 cells, overexpressed DYRK1A localisation was predominantly 
nuclear under basal Wnt signalling activity conditions (Fig. 6A–F left, green). Upon Wnt signalling activation 
however, we observed a statistically significant redistribution of the DYRK1A signal out of the nucleus, with the 
kinase displaying a more diffuse cytoplasmic localisation pattern (Fig. 6A–F right, green). Upon 24-hour DVL1 
overexpression, (Fig. 6E, right, red) DVL1 displayed a distinctive vesicle-like distribution, currently ascribed 
to liquid-liquid phase transition66,67. Remarkably, DYRK1A almost completely redistributed to the cytoplasm, 
showing substantial co-localisation with DVL1 (Fig. 6E, right, yellow). This finding is in accordance with the 
observed DYRK1A-DVL1 protein interaction (Fig. 4B), and might constitute the basis for enhanced Wnt sig-
nalling activity upon overexpression of DYRK1A (Fig. 5E). We also sought to initially determine the subcellu-
lar localisation, if any, of our reported DKK3-DYRK1A interaction (Fig. 7). When co-expressed with DKK3 in 
HEK239 cells, DYRK1A displayed prominent cytoplasmic distribution (Fig. 7 top right, green), whilst DKK3 
accumulated towards the cell membrane (Fig. 7 bottom left, red). Within this site, several areas of increased 
signal co-localisation with DYRK1A were observed (Fig. 7 bottom right and detail boxes, yellow). Whilst this 
interaction remains to be further characterised, our preliminary data suggest that DKK3 and DYRK1A might 
functionally interact at the cell membrane. Given the above discussed interaction with DVL1, which our findings 
indicate may result in Wnt signalling modulation, we suggest that DKK3 might further modulate this interaction.
Overall, these data further support the notion of a strong, bilateral functional relationship between DYRK1A 
and Wnt signalling, whereby DYRK1A modulates pathway activity, and the cascade itself regulates DYRK1A 
localisation (Fig. 8).
Discussion
Here, we showed for the first time dysfunction of Wnt/β-catenin signalling in human DS (Fig. 1). This key devel-
opmental pathway is well placed to underlie many of the wide-ranging features of DS, and particularly the neu-
rodegeneration found in AD-DS18–24. Our data adds further evidence that the DS transcriptome is deregulated 
beyond Hsa21 genes (Figs 2 and 3 and6,68,69 and supports recent findings of overall cell signalling defects in DS70,71. 
We hereby propose that dysfunction of the Wnt signal transduction pathway contributes to DS phenotypes. 
Chronic Wnt dysregulation, due to overexpression of modulators on Hsa21, in particular DYRK1A, may effec-
tively extend the dosage imbalance effects of one gene to a high number of secondary target genes.
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This conclusion is supported by our combined genetic and biochemical analyses of human DS and Tc1 mouse 
hippocampal samples (Figs 1–3). Wnt signalling activity was consistently downregulated in the hippocampus of 
Tc1 mice and human DS individuals. In the former, downregulation of Wnt signalling was suggested by transcrip-
tional profiles as well as reduced active β-catenin protein levels. Given the premature onset of AD dementia in 
human DS50, whereby pathology manifests as early as the third decade of life, initial Wnt investigation in the Tc1 
model focused on young adult mice. Our findings thus suggest that hippocampal Wnt signalling reduction may 
Figure 5. DYRK1A is a bimodal canonical Wnt signalling modulator in a human cell line. (A) DYRK1A 
inhibition reduces levels of LiCl-induced canonical Wnt signalling activity quantified via TOPflash luciferase 
assay. SH-SY5Y cells stably expressing the TCF-LEF luciferase reporter (n = 9) were treated with 40 mM LiCl or 
NaCl control for 5 hours with or without 25 μM EGCG, 25 μM INDY or 10 μM Harmine. 0.1% ethanol and 0.1% 
DMSO were employed as negative control treatments for EGCG and INDY/Harmine, respectively. All inhibitors 
significantly reduced activation (blue bars). Heat map represents log2fold changes/NaCl alone for individual 
luciferase-expressing cultures. (B) same as (A) but with 50 ng/ml Wnt3a stimulation. All inhibitors but EGCG 
significantly reduced activation (blue bars). (C) The inhibitory effect of INDY on LiCl-induced activation is 
dose-dependent. Doses of 1–100 μM INDY (n = 9) were administered for 5 hours and luciferase activity was 
plotted as percentage of control treatment. Linearity was observed (P < 0.0001, R2 = 0.64, f(x) = −0.7× + 83). 
Heat map represents values normalised to LiCl +0.1% DMSO for individual cultures. (D) Effect of INDY in 
live, non-lysed stable SH-SY5Y cells (n = 9). Samples were treated as in (A,B) with or without 25 μM INDY, 
and imaged employing the IVIS system. (E) Effects of DYRK1A expression in the SH-SY5Y line. Cells (n = 27) 
were co-transfected with 0.25 μg/ml HA-DYRK1A, DVL1, both, or empty vector controls for 24 hrs. 0.25 μg/ml 
TOPflash and 0.025 μg/ml constitutively active renilla luciferase constructs were employed as reporters, with 
signal quantified as TOPflash/Renilla ratio. All values expressed as log2fold relative to empty vector transfection. 
Adjacent graph demonstrates same experiment employing mutant reporter construct FOPflash-luciferase. Heat 
map represent values for individual luciferase-expressing cultures. (F) Immunoblot demonstrating DYRK1A 
expression is sufficient to enhance total amounts of GSK3β protein and alter its phosphorylation status at Ser9. 
SH-SY5Y cells (n = 12) were transfected with 0.5 μg/ml HA-DYRK1A for 24 hrs. Total levels of GSK3β were 
enhanced, and phosphorylation at Ser9, as expressed by ratio to total protein, was significantly reduced.
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represent an early pathological process, potentially underlying the premature development of AD in human DS. 
It would nevertheless be of interest to determine whether, in the Tc1 mouse, similar changes might also be present 
at a later time point, as already observed in human DS hippocampi. This should be addressed in future studies.
Indeed, current knowledge of Wnt signalling in neuronal function indicates that downregulation of the path-
way is likely to contribute to neurodegenerative processes, especially during adulthood18–24. Further reflecting 
underlying abnormalities in Wnt signalling, we detected changes in DKK3 levels in Tc1 and human DS hip-
pocampi. DKK3 is a member of the Wnt inhibitor Dickkopf family, which is involved in hippocampal devel-
opment and AD20,72. Consistent with our data, DKK3 is reportedly elevated in CSF and plasma of sporadic AD 
patients73. It is presently unclear why the DKK3 alterations differ between the Tc1 mouse and humans. This is 
possibly due to late-stage overall dysfunction of the Wnt secretory machinery in AD-DS, and further investiga-
tion is required.
We suspect, however, that Wnt signalling might not necessarily be ubiquitously downregulated in DS. 
The complexity of Wnt function in development, health and disease generally supports the possibility of 
multi-directional alterations in DS9,74,75, although this remains to be determined. By contrast, mice with dupli-
cated Hsa21 syntenic regions on Mmu10 or 17 presented no overall effect on active β-catenin (Fig. S2). Therefore, 
we assumed that the overexpression of genes located on the Hsa21 syntenic region on Mmu16 affects canonical 
Wnt signalling in the hippocampus. This led to our hypothesis of DYRK1A as a candidate Wnt modulator in 
DS, given its known functional interaction with Wnt components28,31,35 and important contribution to DS and 
AD37–45.
Figure 6. Subcellular localisation of DYRK1A is affected by Wnt signalling activation. (A) Airyscan microscopy 
of 5-hour 40 mM NaCl (left) or LiCl (right) treatment in HeLa cells. DYRK1A is pseudocolored in green, DAPI 
(nuclear stain) in blue, and phalloidin (F-actin stain) in magenta (applies to all panels). DYRK1A localised to 
the nucleus when expressed alone (left), but redistributed to the cytoplasm in the presence of wnt activation. 
(B) Nuclear/cytoplasmic fluorescence ratio quantified from the same conditions as in (A) but in HEK-293 
cells, demonstrating a significant reduction in nuclear localisation. (C) Same as (A) but employing 5-hour PBS 
as basal control and 50 ng/ml Wnt3a to achieve Wnt activation. Decreased DYRK1A nuclear fluorescence was 
observed (right). (D) Same as (B) but for experiment in (C). A significant reduction in the nuclear/cytoplasmic 
ratio was observed. (E) Same as (A,C) but employing 24-hour overexpressed 0.5 μg/ml HA-DYRK1A ± DVL1-
FLAG (red) with prominent cytoplasmic co-localisation in the presence of DVL1. (F) Same (B,D) but for 
experiment in (E). A significant reduction in the nuclear/cytoplasmic ratio was observed.
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DYRK1A was able to regulate total and pSer9 GSK3β levels in SH-SY5Y cells, leading to Wnt signal inhi-
bition under basal conditions (Fig. 5F). This is perhaps not surprising, given the known priming relationship 
between the two kinases. Evidence suggests DYRK1A may employ priming phosphorylation to target substrates 
for further modification by GSK3β and subsequent degradation, independently of Wnt function28,76–78. A similar 
mechanism might however allow DYRK1A to direct GSK3β phosphorylation to Wnt signalling components. 
The presence of several DYRK1A interactions with Wnt-associated proteins, most importantly DVL1 and DKK3 
(Figs 4, S3 and 4) suggests multiple access routes for DYRK1A modulation of the Wnt pathway. It is particularly 
interesting that DKK3, which we found to be altered in the DS hippocampus, interacts with DYRK1A via its 
nuclear speckle-localising sequence59. This suggests potential regulation of DYRK1A localisation by DKK3, a 
possibility which warrants further study. The bimodal effects of DYRK1A on Wnt signalling activity support its 
modulatory role further (Figs 5A–E, 7). Overall, DYRK1A enhanced active Wnt signalling while reducing basal 
activity levels. Consistently with this idea, we showed subcellular re-localisation of DYRK1A from the nucleus27,59 
to the cytoplasm upon Wnt signalling activation (Figs 6 and S6). This suggests that bimodal Wnt regulation 
by DYRK1A may be dependent upon its subcellular distribution and resulting substrate preference. Nuclear 
DYRK1A may thus suppress basal Wnt signalling activation by a transcriptional process27. By contrast cytoplas-
mic DYRK1A, possibly working in synergy with its interaction partner DVL1, increases active Wnt signalling 
further. This novel Wnt enhancing property of DYRK1A is supported by recent findings in pancreatic β-cells79. It 
is possible that these novel properties of DYRK1A may account for, or at least contribute to, the beneficial effects 
of Lithium treatment in the Ts65Dn DS mouse model reported by Contestabile et al.63. The notion of a functional 
Wnt-DYRK1A relationship is also supported by our preliminary identification of a physical interaction of this 
kinase with DKK3 (Figs 4, S3 and 4), which might occur intracellularly at the plasma membrane (Fig. 7). Whilst 
we do acknowledge that DKK Wnt antagonists are mostly known as secreted proteins72, evidence exists suggesting 
Figure 7. Subcellular localisation of DYRK1A and DKK3. 24-hour overexpression of 0.5 μg/ml HA-DYRK1A 
(green) ± DKK3 (red) showed cytoplasmic distribution for both proteins with some co-localisation near the 
plasma membrane.
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DKK3 might also possess intracellular functions80. Thus we preliminary propose that, DKK3 might further con-
tribute to bimodal Wnt-DYRK1A modulation by interacting with the latter kinase at the cell membrane.
The consequence of this dualistic effect in DS might be a complex spatiotemporal alteration in Wnt target 
gene expression throughout life (Fig. 8). Given that the default level of DYRK1A expression is chronically ele-
vated in this condition, Wnt signalling might be proportionally affected as a consequence, in a direction deter-
mined by local activation states. This implies that tissue types with low basal Wnt signalling levels, such as adult 
hippocampal neurons, may suffer from further downregulation, as observed in Tc1 mice and DS individuals. 
Indeed, under-activation of Wnt signalling in the adult hippocampus results in synaptic loss and neurodegen-
eration20,81,82 and is expected to disrupt key mechanisms such as neurogenesis83,84 and long-term potentiation85. 
Conversely, rapidly proliferating tissues such as fibroblasts may undergo aberrant Wnt over-activation. It is well 
established that enhanced Wnt activity significantly correlates with development of several cancer types9,74,75,86. 
Thus, Wnt dysfunction might potentially contribute to the known differential cancer susceptibility in DS, such as 
the enhanced risk of leukemias and reduced incidence of solid tumours87. High basal Wnt levels in proliferative 
haematopoietic cells might, for example, be exacerbated by DYRK1A overexpression, which does indeed play a 
role in DS-related leukemias88. This intriguing possibility, however, remains to be investigated.
Conclusions
Overall, the key implication of our findings is that Wnt signalling regulation by DYRK1A may be established 
as a novel target for therapeutic development in DS neuropathology and beyond. Such a strategy might entail a 
dual approach: (1) Targeting aberrant DYRK1A activity in particularly Wnt-susceptible tissue types such as the 
adult hippocampus. (2) Directly targeting under/over-activation of Wnt signalling and target genes, depending 
on tissue-specific directional changes. Both approaches are particularly attractive, chiefly because Wnt signalling 
Figure 8. Diagrammatic model summarising the proposed bimodal Wnt signalling regulation by DYRK1A, as 
reported in Figs 4–6. (A) Basal/Inactive Wnt signalling conditions, whereby nuclear translocation of β-catenin 
is prevented via its proteasomal degradation, mediated by the destruction complex. (B) Active Wnt signalling, 
whereby Frizzled receptor stimulation by ligands results in membrane recruitment of the destruction complex, 
cytosolic release and nuclear translocation of ‘free’ β-catenin followed by TCF/LEF binding and transcriptional 
activation of Wnt target genes. (C) DYRK1A overexpression alone results in significant downregulation of Wnt 
signalling activity (Fig. 5E, blue) along with prominent nuclear localisation of the DYRK1A protein (Fig. 6A–F, 
left green). (D) DYRK1A-DVL1 co-expression (ie under active Wnt signalling conditions) significantly enhances 
Wnt signalling activation levels (Fig. 5E, red) and leads to cytoplasmic accumulation of DYRK1A (Fig. 6E,F, 
right green), likely mediated by direct interaction with DVL1 (Figs 4B,D and 6E, right yellow). This DYRK1A 
redistribution pattern is also observed following Wnt stimulation with LiCl or Wnt3a (Fig. 6A–D, right green). 
(E) Consistently, DYRK1A inhibition results in decreased levels of active Wnt signalling following LiCl or 
Wnt3a treatment, relative to pathway stimulation alone (Fig. 5A–D). APC - Adenomatous polyposis coli; β-cat - 
β-catenin; DKK - Dickkopf-related protein; DVL - Disheveled 1; GSK-3β - Glycogen synthase kinase 3β; KRM 
- Kremen co-receptor; LRP5/6 - Low-density lipoprotein receptor-related protein 5/6; P - Phosphorylation; 
TCF/LEF - T-cell factor/lymphoid enhancer factor.
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and DYRK1A have been heavily investigated therapeutically. In the context of cancer, a high number of pharma-
ceutical agents which target Wnt signalling on multiple levels already exists14,89,90. Stimulation of neuronal Wnt 
signalling, on the other hand, is currently viewed as a promising strategy in AD and other neurodegenerative 
diseases18,63,91,92. Similarly, employment of DYRK1A inhibitors to target cognitive deficits in DS and β-cell dys-
function in diabetes is a rapidly developing field27,45,60,62,93,94. A variety of therapeutic strategies can be envisioned 
at multiple developmental stages. Administration of a combined Wnt-DYRK1A normalising therapy in utero 
might prove critical in tackling developmental abnormalities in DS. Likewise, Wnt signalling stimulation may 
be beneficial in later life, especially in the context of AD-DS. Thus, eventual clinical translation of our findings 
might open avenues for treatment strategies in DS, aimed at normalising Wnt signalling function throughout life. 
We hope that future research efforts will expand on our proposed model, in order to tackle this condition and 
improve the quality of life for those affected by it.
Methods
Study design. Sample size. Selected based on sample/tissue availability following standard procedures for 
each technique, in order to generate statistically significant results, see relevant sections of materials and methods.
Data inclusion/exclusion criteria. All data collected for each experiment presented were included.
Outliers. No outliers were excluded, all data are presented as box plots including minimum and maximum 
values.
Replicates. For all mouse and human DS immunoblotting experiments, samples were quantified in duplicate 
and averaged, reported n for these experiments represent averaged duplicates. For example, n = 8 Tc1 hippocam-
pal samples indicates analysis of 16 total samples (including 8 WT controls) measured twice (total of 32 val-
ues quantified) in separate gels and averaged. For all cell-based experiments, a minimum of three independent 
repeats was performed, with variable sample sizes reported in the main text and legends. In this case, n represents 
all individual replicates added together. For further information on the above and all other analyses conducted 
see Supplementary Tables S4 and 5 and relevant sections of materials and methods.
Pre-specified hypotheses:
 1. Wnt signalling dysregulation may be associated with gene expression and/or protein profiles of DS mouse 
models and humans.
 2. One or more Hsa21-encoded protein may functionally regulate Wnt/β-catenin signalling, particularly:
 A. Interact with Wnt components
 B. Affect luciferase-reported Wnt signalling activity
Hypotheses suggested after initiation of the data analyses:
 1. The Wnt phenotypes observed in DS models and humans are likely to be mediated by Mmu16 Hsa21 
orthologs.
 2. Lack of APP expression in the Tc1 mouse indicates DYRK1A as a more likely Wnt modulator in our current 
system, and this gene was thus tested for pre-specified hypotheses 2A,B
 3. Wnt signalling activation states may affect subcellular distribution of DYRK1A,
Research subjects or units of investigation. Tc1 mouse hippocampal RNA; Tc1, Dp(17)1Yey and Dp(10)1Yey hip-
pocampal samples, post-mortem hippocampal samples of DS patients; Hybrigenics-generated Y2H interaction 
database from the Inter-PP project (Jerome LeJeune Foundation); SH-SY5Y, HEK-293 and HeLa cell cultures.
Experimental design. Controlled laboratory experiments, see relevant sections of main text and materials and 
methods for types of measurements made.
Statistical analysis and graphs. RNAseq data was analysed by Deseq. All P values reported were adjusted 
for false discovery rate (FDR). All IPA-generated P values reported for pathway, upstream regulator, and disease 
and function analyses were produced by Fisher’s exact test and thresholded at P < 0.05. STRING protein inter-
action networks for the DYRK family were analysed by STRING, correcting for FDR. All other statistical anal-
yses were performed in GraphPad Prism 07a. For human and mouse biochemistry and qPCR reported P values 
were calculated by two-tailed Mann-Whitney U test, due to the non-Gaussian nature of the datasets. DYRK1A 
expression experiments and immunocytochemistry were also analysed with the same test. For all Luciferase 
experiments, the data were analysed by Kruskal-Wallis test with post-hoc correction for multiple comparisons 
by two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli, due to the non-Gaussian nature of 
the datasets. All P values there reported represent FDR-adjusted q values. For dose-response curve experiments 
(Fig. 5C), treatment groups/doses were matched by individual experimental repeat and analysed by Friedman 
test with the same correction as above. Linear regression was calculated on % of maximum (LiCl + DMSO) val-
ues, throughout the entire dose range of 1–100 μM. See Supplementary Tables S4 and 5 for additional info on 
all statistical tests performed. All heat maps and box plots were created in GraphPad Prism 07. In all cases, box 
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span represents first to third quartiles, bands represent the median of each sample group, and whiskers represent 
minimum/maximum values. Throughout this study, relative ‘increases’ were colour coded as red, and ‘decreases’ 
as blue in a combination of hues safe for all types of colour vision deficiency. See relevant sections of materials and 
methods for additional details on quantification and processing methods employed.
Expression constructs. pCMV5-HA-DYRK1A and pCS2-DKK3-FLAG were obtained from MRC 
PPU Reagents, while pCDNA3.1-FLAG-β-catenin was a gift from Eric Fearon (Addgene plasmid #16828). 
pRK5-FLAG-DVL1 was generated in-house as described previously95. M50 Super 8X TOPflash and M51 Super 
8X FOPflash were gifts from Randall Moon (Addgene plasmids #12456 and #12457)96. pTK-Renilla (Renilla) 
was purchased from Promega. All plasmid were verified by DNA sequencing at MRC PPU Sequencing Services 
(Dundee, Scotland, UK).
Animal husbandry, welfare, and tissue sampling. Tc(Hsa21)1TybEmcf (Tc1), Dp(17Abcg1-Rrp1b)1Yey 
(Dp(17)1Yey), and Dp(10Prmt2-Pdxk)1Yey (Dp(10)1Yey), mice47,54 were bred at the Francis Crick Institute in 
specific pathogen free conditions, in a controlled environment and in accordance with the MRC Responsibility in 
the Use of Animals for Medical Research (1993) guidelines. Tc1 mice were maintained by crossing to (C57BL/6J 
× 129S8)F1 mice; all other strains were maintained by crossing with C57BL/6J mice. All animals were euthanised 
by cervical dislocation in accordance with the Animals (Scientific Procedures) Act 1986 and European Directive 
2010/63/EU. For immunoblotting experiments, brains were collected from 160 ± 28 days days old male Tc1 mice 
and 131 ± 7 days old male Dp(17)1Yey/Dp(10)1Yey mice, washed in phosphate-buffered saline (PBS) and dis-
sected into bilateral cortical, hippocampal and brainstem fractions. Samples were then snap-frozen in liquid 
nitrogen and stored at −80 °C. Prior to each experiment, all mouse hippocampal samples were homogenised via 
mechanical disruption, at 4 °C, in 500 μl brain lysis buffer [50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2 and 
1% (v/v) NP-40, 1x complete protease inhibitor cocktail (Roche), 1x Halt phosphatase inhibitor cocktail (Thermo 
Scientific™)]. Each lysate was clarified at 4 °C by centrifugation at 20,000 g and denatured via addition of 10x 
sample reducing agent and 4x LDS sample loading buffer (Thermo Scientific™) and heating at 99 °C for 5 min. All 
samples were assayed for protein concentration by bicinchoninic acid (BCA) assay (Thermo Scientific™).
Cell maintenance. For luciferase, coIP experiments and imaging experiments, SH-SY5Y and HEK293 cells 
were grown to 106-7 cells/ml (counted with Muse® count and viability kit) and maintained at 37 °C and 5% CO2 
in 10 ml Dulbecco’s modified Eagle’s medium (DMEM) enriched with 10% (v/v) foetal bovine serum (FBS), 100 
U/ml penicillin G, 100 μg/ml streptomycin and 2 mM glutamine. For immunocytochemistry experiments, HeLa 
cells (ATCC) were grown in phenol red-free Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 
10% (v/v) FBS (Corning), 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin at 37 °C and 5% 
CO2.
Generation of SH-SY5Y cells stably expressing the the TCF/LEF-Luciferase reporter (Stable 
TOPflash). Stable TOPflash SHSY5Y cells (Fig. 5A–D) were made in a two-step process. Firstly, the TCF/
LEF-responsive promoter and luciferase reporter from M50 Super 8x TOPflash96 was cloned into a plasmid with 
suitable antibiotic resistance for selection in mammalian cells. To this end, the CMV promoter was removed 
from pcDNA3 by restriction digestion with BglII and NotI, and a NotI-BamHI fragment from M50 Super 8X 
TOPflash ligated into these sites. The responsiveness of the resultant plasmid to transient transfection with DVL1 
was confirmed by luciferase assay and found to be approximately ~25% that of M50 Super 8x TOPflash. Secondly, 
this plasmid was stably transfected into SH-SY5Y cells. The plasmid was linearised by PvuI digestion and trans-
fected into SH-SY5Y cells, with stably transfected cells selected for resistance to G418 (800 μg/ml) following 
standard procedures. Twelve clonal cell lines were established and compared for basal luciferase expression and 
fold-induction in response to 30 mM LiCl treatment. Clone #3 was chosen for experiments performed in this 
study, as the cell line displaying the greatest sensitivity to Wnt pathway activation.
Transfection. Cells were treated with 3:1 FuGENE® HD transfection Reagent (Promega) for 24 hrs to achieve 
transient gene expression. In all luciferase experiments, 0.25 μg/ml DNA per construct/condition were trans-
fected. In DYRK1A expression experiments and coIPs, 0.5 μg/ml DNA per construct/condition were transferted. 
Cells were subsequently lysed with in 1 ml cell/brain lysis buffer [150 mM NaCl, 50 mM Tris (pH 7.5), 2 mM 
EDTA (pH 8), 1% (v/v) Triton X-100, 1x complete protease inhibitor cocktail and 1X Halt phosphatase inhibitor 
cocktail]. Lysate clearing and denaturing was achieved in the same conditions as above.
Post-mortem Human DS samples. All post-mortem human brain samples were processed in accordance 
with the Human Tissue Act 2004 and directives from the Human Tissue Authority (UK). The study was reviewed 
and approved by NHS Research Ethics committee, London-Queen Square. Samples were provided, anonymised, 
by the Newcastle brain bank, from 55 (±11) and 56 (±12) years old DS/AD patients and age-matched euploid 
controls, respectively (Fig. 1A and Table S1). All patients had granted full research consent. 10 mg of frozen tissue 
from hippocampal and cortical samples was excised in a sterile environment and immediately triturated with a 
plastic pestle in 100 μl brain lysis buffer. All samples were then cleared and denatured as described above, and 
protein concentration was measured as described.
Pharmacological treatment of cells. Wnt signalling activation was achieved by treatment with either 
40 mM LiCl or 50 ng/ml Wnt3a (R&D) for 5 hrs. 40 mM NaCl and 0.1% PBS were employed as control treat-
ments, respectively. The DYRK1A inhibitors Epigallocatechin-3-gallate EGCG (Sigma-Aldrich), INDY (Tocris) 
and harmine (Tocris) were prepared according to manufacturer’s instructions and administered at previously 
1 4Scientific RepoRts |          (2019) 9:7322  | https://doi.org/10.1038/s41598-019-43820-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
published doses of 25 μM (EGCG), 1–100 μM (INDY) and 10 μM (harmine) for 5 hr. 0.1% Ethanol or 0.1% DMSO 
were employed as controls for EGCG and INDY/harmine, respectively.
Western blotting. Approximately 10 μg protein from all mouse, human cell line and human post-mortem 
samples were loaded into 10 or 20-well 4–12% (w/v) BisTris pre-cast gels (Thermo Scientific™) and subsequently 
transferred onto polyvinylidine fluoride (PVDF) membranes (Biorad). Membranes were blocked for 1 hr in 
Tris-buffered saline, 0.1% Tween 20 (TBS-T) with 5% (w/v) non-fat dry milk. All primary antibodies were admin-
istered overnight in blocking buffer, at 4 °C. Following at least three washes in TBS-T, membranes were treated 
with HRP-conjugated secondary antibodies for 1 hr at room temperature and washed again. All primary and 
secondary antibodies were employed at 1:2000 dilution, except for the β-actin antibody used 1:5000 (Table S6). 
Protein bands were visualised with SuperSignal West Pico/Femto Chemiluminescent HRP Substrate (Thermo 
Scientific™). Images were acquired with a SynGene GeneGnome Imaging system with varying exposure times 
from 10 sec to 1 min depending on signal strength.
Luciferase assays. All luciferase assays were carried out in 6-well plates and as previously described97. For 
experiments depicted in Fig. 5A–C,E, a Dual Luciferase Reporter assay kit (Promega) was employed either in 
stable TOPflash cells (Fig. 5A–C) or via transient expression of 0.25 and 0.025 μg/ml of TOP/FOPFLASH and 
renilla luciferase constructs in unmodified SH-SY5Y, respectively (Fig. 5E). For the latter, 0.25 μg/ml of empty 
vector and/or HA-DYRK1A and FLAG-DVL1 were also co-transfected as described above. Transient expression 
of DYRK1A was assessed against basal and DVL1-driven canonical Wnt signalling activity at 24 hours. For results 
in Fig. 5D, luciferase activity was measured in live cells from the TOPflash stable line, by enriching DMEM with 
150 ug/mL D-luciferin (Systems Biosciences) and employing the IVIS system (Perkin-Elmer) to image plates 
20 min post-treatment.
Co-immunoprecipitation. HEK293 cells were co-transfected with 0.5 μg/ml HA-DYRK1A and 0.5 μg/ml 
FLAG-DVL1/β-catenin-FLAG/DKK3-FLAG or relative empty controls and lysed as described above. Prior to 
denaturing, 40 μl of anti-FLAG M2 affinity gel (Sigma) were added to 1 ml of each lysate. Following 1 hr of rota-
tional incubation at 4 °C, the gel was washed five times by centrifugation and resuspension in cell lysis buffer. 
150 ng 3xFLAG peptide (Sigma) were used to elute the fusion proteins. Eluates were denatured as described 
above. Endogenous coIPs were also performed in HEK293 cells under basal conditions, employing Protein A 
Dynabeads® (Thermofisher) conjugated to a DVL1 or DYRK1A antibody, following protocols supplied by the 
manufacturer. Each coIP was performed independently at least three times.
RNAseq. Total male Tc1 hippocampal RNA (n = 3, 3 months) was extracted using miRNeasy mini kit 
(Qiagen). Tissue was disrupted using a Tissue-Rupter, as per manufacturer’s instructions and resuspended in 
DNase- and RNase-free water. Total hippocampal RNA sample quality was confirmed by Bioanalyzer (Agilent) 
and libraries were prepared with the TruSeq RNA v2 LS Kit (Ilumina). RNAseq was then performed employing 
the HiSeq system (Illumina).
RNAseq data analysis. Due to the presence of human genes in the Tc1 mouse, a custom reference genome 
was assembled in order to asses expression levels of Hsa21 genes. A standard mouse genome (NCBI build 37.2) 
was combined with the Hsa21 sequence (NCBI build 37.2). The RNAseq data was then aligned to this custom 
genome employing Bowtie (v2.1.0) as part of the Tophat pipeline. Overall count data were then generated, 
employing the dexseq_count.py script, before combining counts for Hsa21 genes and mouse orthologs. The 
resulting data, also including non-Hsa21 genes, was then analysed by Deseq to generate adjusted P values.
Quantitative real-time polymerase chain reaction (qPCR). cDNA preparation. For all qPCR exper-
iments, mRNA was sourced from male Tc1 mouse hippocampus (n = 4, 6 months). For each sample (labeled 
WT/Tc1 A–D), 1 μg mRNA was first cleared of genomic DNA (gDNA) via incubation in 2 μl gDNA Wipeout 
Buffer (2.5–10% trometamol - QIAGEN) and 12 μl RNAse-free ddH20 at 42 °C for 2 min. Following, mRNA was 
reverse-transcribed into cDNA using a QuantiTect. Reverse Transcription Kit (QIAGEN) according to manu-
facturer’s instructions. The resulting ~1 μg (50 ng/μl) cDNA product was stored at −20 °C for experimental use. 
For each sample, an identical reaction was run alongside, substituting the reverse transcriptase with RNAse-free 
ddH20 for usage as a negative control (−RT) to account for any non-specific amplification at the qPCR stage.
Primer and probe design. Exon sequences for AXIN2 and DKK3 were obtained from the e!Ensembl browser 
(http://www.ensembl.org/index.html) selecting for mouse genome. Primers and probes were designed employing 
Primer Express® Software (Life Technology) set on TAQman qPCR design. Primers were specifically engineered 
to bridge exon-exon boundaries. Furthermore, each primer pair and probe was tested for specificity through 
the NCBI reverse ePCR web service (http://www.ncbi.nlm.nih.gov/projects/e-pcr/forward.cgi). FAM™ and 
TAMRA™ were employed as fluorophore and quencher, respectively. Upon delivery, primers were solubilised 
in ddH20 while probes were dissolved in qPCR Probe Dilution Buffer (10 mM Tris-HCl, pH 8, 1 mM EDTA) to a 
100 μM stock concentration and stored at −20 °C according to manufacturer’s instructions.
qPCR and quantification. For experimental use, primer and probe stocks were diluted to 40 μΜ and 5 μM in 
ddH20 respectively. Furthermore, each 50 ng/μl cDNA preparation was diluted 1:10 following routine labora-
tory practice for moderately-to-highly expressed genes. β-actin and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) were employed as control reference genes. Primers and probes for both were labeled with VIC® (Life 
Technology) and quenched by MGB. All reactions were incubated in TaqMan® Gene Expression Master Mix 
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(AmpliTaq Gold® 55 DNA Polymerase (Ultra Pure), Uracil-DNA glycosylase, dNTPs (with dUTP), ROXTM 
Passive Reference, and optimised buffer components). Each experiment was performed in a standard 96-well 
plate format. For all experiments performed in this study, sample WT A was selected as standard. The origi-
nal 50 ng/μl cDNA preparation was diluted 1:5 and then 1:2 serially up to 1:80. All samples and controls were 
loaded in technical triplicate. All experiments were performed employing a 7500 Fast Real-Time PCR System 
(Life Technologies) controlled by homonymous software. The qPCR was ran for a standard duration of approxi-
mately 90 min. For all samples, the CT value for each replicate was normalised to the geometric mean of reference 
gene levels (GAPDH and β-actin). Mean ± SD/SEM were calculated, and all means were then normalised to WT 
A levels.
ULTImate Y2H™ analysis. Yeast two-hybrid screening shown in Fig. 4E was performed by Hybrigenics Services, 
S.A.S., Paris, France (http://www.hybrigenics-services.com). The coding sequence for full length DYRK1A iso-
form 1 (NCBI reference (NM_001396.3) was PCR-amplified and cloned into pB27 as a C-terminal fusion to LexA 
(LexA-DYR1A), and into pB29 as an N-terminal fusion to LexA (DYR1A-LexA). The constructs were checked 
by sequencing and used as a bait to screen a random-primed Adult Brain cDNA library constructed into pP6. 
pB27 and pB29 derive from the original pBTM116 vector98, and pP6 is based on the pGADGH plasmid99. For 
the N-LexA-DYRK1A-C and the N-DYRK1A-LexA-C bait constructs, 65 million (6.5-fold the complexity of the 
library) and 115 million (11.5-fold the complexity of the library) clones were screened using a mating approach 
with YHGX13 (Y187 ade2-101::loxP-kanMX-loxP, matα) and L40ΔGal4 (mat a) yeast strains as previously 
described100. 269 and 253 His+ colonies, respectively, were selected on a medium lacking tryptophan, leucine 
and histidine and 2 mM 3-AT for N-LexA-DYRK1A-C and 5 mM 3-AT for N-DYRK1A-LexA-C to maintain a 
strong selectivity and manage the slight autoactivation. The prey fragments of the positive clones were amplified 
by PCR and sequenced at their 5′ and 3′ junctions. The resulting sequences were used to identify the correspond-
ing interacting proteins in the GenBank database (NCBI) using a fully automated procedure.
PBS scoring. A confidence score (PBS, for Predicted Biological Score) was attributed to each interaction. 
The PBS relies on two different levels of analysis. Firstly, a local score takes into account the redundancy and 
independency of prey fragments, as well as the distribution of reading frames and stop codons in overlapping 
fragments. Secondly, a global score takes into account the interactions found in all the screens performed at 
Hybrigenics using the same library. This global score represents the probability of an interaction being nonspe-
cific. For practical use, the scores were divided into four categories, from A (highest confidence) to D (lowest con-
fidence). A fifth category (E) specifically flags interactions involving highly connected prey domains previously 
found several times in screens performed on libraries derived from the same organism. Finally, several of these 
highly connected domains have been confirmed as false-positives of the technique and are now tagged as F. The 
PBS scores have been shown to positively correlate with the biological significance of interactions101.
Immunocytochemistry sample preparation. HeLa cells, cells were seeded at ~60% confluency into No. 1.5 imag-
ing chambers (Lab-Tek) coated with 400–600 μg/ml Matrigel (Corning) and transfected immediately using 
Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturer’s specifications. HA-DYRK1A was 
transfected at 0.25 μg/ml, or else co-transfected with FLAG-DVL1 or FLAG-DKK3 at the same concentration. 
Wnt3a and LiCl treatment including the appropriate controls were conducted as detailed above 5 hours prior 
to fixation. After 18 hours cells were fixed with 4% (w/v) paraformaldehyde (PFA) for 20 min at room tempera-
ture (RT). Samples were then permeabilised with 0.2% (w/v) saponin (Sigma-Aldrich) for 30 min, and blocked 
in 5% (v/v) donkey serum (Sigma-Aldrich) doped with 0.05% (w/v) saponin for 1 hour at RT. FLAG and HA 
primary antibodies (Sigma-Aldrich) were diluted in block to 1:100, added to cells, and incubated overnight 
at 4 °C. Secondary anti-mouse and anti-rabbit antibodies conjugated to Alexa 488 and Alexa 594 (1:1000; Life 
Technologies) were made in block and incubated with samples for 30 min at RT. A 1:5000 Hoescht 33258 and 
1:1000 Phalloidin 647 (both ThermoFisher Scientific) dilution in PBS was incubated for 30 mins at RT to label the 
nucleus and F-actin respectively. Cells were thoroughly washed and Imaging was performed in fresh PBS,
HEK293 cells were seeded at ~60% confluency onto glass coverslips previously coated with 0.1 mg/ml 
poly-D lysine and grown into 6-well plates. Transfection was performed as above but employing 3:1 fuGene HD 
(Promega) as transfection reagent. Treatment was also performed as above. After 18 hours cells were fixed with 
4% (w/v) paraformaldehyde (PFA) for 20 min at RT. Samples were then permeabilised for 30 min in 0.5% (w/v) 
Triton-X 100, and blocked in 5% (w/v) FBS with 0.05% (w/v) Triton-X 100. The DYRK1A (Abcam) rabbit poly-
clonal primary antibody was incubated as above at 1:500 dilution. Secondary anti-rabbit Alexa 488 was incubated 
as above. A 1:1000 DAPI (ThermoFisher Scientific) dilution in block buffer was incubated for 30 mins at RT to 
label the nucleus.
Airyscan and confocal imaging. Airyscan imaging was performed using a Zeiss 880 outfitted with an Airyscan 
module. Data was collected using a 63 × 1.4 NA objective and immersion oil optimised for 30 °C (Carl Zeiss). 
Colors were collected sequentially by frame to minimise crosstalk, and Airyscan processing was performed using 
the Airyscan module in the commercial ZEN software package (Carl Zeiss). Confocal imaging was performed 
using a Zeiss 710, also using a 63 × 1.4 NA objective and immersion oil.
Confocal imaging quantification. Confocal data collected from the Zeiss 710 was used to quantify the nuclear 
to cytoplasmic ratio of HA-DYRK1A under Wnt stimulation and control conditions. Bitplane (IMARIS) was 
used to create masks to the nucleus and entire cellular volume. Alexa 488 conjugated HA-DYRK1A fluorescence 
intensity was integrated across both masks. The nuclear signal was subsequently subtracted from the signal of the 
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entire cellular volume, providing cytoplasmic HA-DYRK1A fluorescence. Data is displayed as a ratio of nuclear 
to cytoplasmic fluorescence intensity.
Western blot and luciferase quantification. Protein bands were quantified from non-processed, raw image files 
only, directly at the acquisition stage (Syngene GeneGnome system). Automatic background correction was 
applied to all values before normalising each protein of interest to its relevant β-actin loading control. For phos-
pho/de-phosphoproteins analysed (active β catenin, pS9 GSK3β) values were normalised to total amounts of the 
relative protein, which were also normalised to β-actin. Values were further normalised to the mean of the control 
condition (WT for mice, euploid for humans, and empty vector control for cells) for each individual experimen-
tal repeat. For all luciferase experiments, TOP/FOPFLASH values quantified alone (Fig. 5A–D) or as a ratio to 
renilla luciferase activity (Fig. 5E) were normalised to the average control condition in each repeat. Data were 
then log2-transformed prior to analysis. This step was undertaken to more appropriately visualise lucid erase data, 
due to large fold changes in some cases. In Fig. 5C, the mean normalised signal of treated cells with LiCl +0.1% 
DMSO was assumed as maximum response, and all other values expressed as percentages of the former. For 
IVIS experiments (Fig. 5D), preset circular regions of interest (ROIs) were applied to each well, and background 
was automatically corrected for by subtracting from an average background ROI. These data were then analysed 
directly without log2-transformation, to more appropriately reflect depicted light emission quantified by IVIS. For 
all sample groups, mean, SD and SEM were calculated.
Image processing. In all western blots, no image processing was performed, presenting the blot results in raw 
format. Raw.sgd files were converted to.tiff and colour-inverted to display background as white/grey. Figures 1, 3, 
4 and 5 display horizontally cropped sections of representative blots, and black lines indicate where the image was 
occasionally cropped vertically (see Fig. S1 for all original, non-cropped blots detailing areas displayed in figures 
and related loading controls). All co-IP gels in Fig. 4A–D are presented from 1 representative repeat. For IVIS 
luciferase experiments (Fig. 5D), minimum and maximum display levels were automatically set by the system 
according to measured signal, independent of quantification.
Ingenuity pathway analysis. The Qiagen Ingenuity® Pathway Analysis (IPA®) tool was employed to probe 
mouse and human RNAseq datasets for alterations in primary Wnt components and upstream regulators. For 
Fig. 3B–D, Tc1 RNAseq analysis was performed on a dataset of significantly altered genes at adjusted P < 0.05. 
In all cases, IPA analysis parameters were left at default, searching only for direct relationships and for human, 
mouse and rat orthologs. For each dataset, pathway, upstream regulator and diseases/functions analysis were 
performed. Curated gene lists were produced by manually selecting all affected genes in the dataset indicated as 
primary Wnt components, or under regulation of β-catenin/Wnt3a. Curated lists of upstream regulators were 
generated by searching for Wnt-related proteins contained in the analysis output. Z-scores and molecular activity 
predictions (MAPs) were generated automatically by IPA.
STRING and cytoscape network analysis. The protein interaction database and analysis tool STRING 
v10.058 was employed to build the networks in Fig. 4E,F. To achieve this goal, DYRK1A was placed as the hub of 
a basic network (Fig. 4E, red circles) comprising: (1) The Hybrigenics-reported DKK3 interaction; (2) Previously 
published interactions (solid black lines) between DYRK1A, p-120 catenin (CTNND1)31, and GSK3β35; (C) 
Experimentally detected DKK3 and DVL1 interactions (dotted black lines). Components of the basic network in 
Fig. 4E were used as starting nodes, selecting human as default organism. This initial network, or first shell, was 
enriched with the 10 best-scoring interactors. A further shell was then added, comprising the 10 best-scoring 
secondary interactors of the network. The network diameter, or distance between each node, was limited to 3, 
meaning that each node is no more than one degree of interaction away from any other. This was done to better 
reveal a highly interconnected network. The resultant network (Fig. 4F) has 140 edges and 25 nodes. The network 
was then imported into the Cytoscape network analysis tool and its visual properties were modified to distin-
guish amongst node types and visually aid description of the results. The network was displayed employing a 
spring-embedded layout, manually adjusted to reflect the known structure of canonical Wnt signalling.
Ethics approval and consent to participate. The use of animals was conducted in line with the ethical 
principles of Replacement, Reduction and Refinement (3Rs). All animal studies were approved by the University 
College London Animal Welfare and Ethical Review Body (AWERB) and licensed by the home office.
Data Availability
All raw data are available on request.
References
 1. Sherman, S. L., Allen, E. G., Bean, L. H. & Freeman, S. B. Epidemiology of Down syndrome. Ment Retard Dev Disabil Res Rev 13, 
221–227, https://doi.org/10.1002/mrdd.20157 (2007).
 2. Hernandez, D. & Fisher, E. M. Down syndrome genetics: unravelling a multifactorial disorder. Hum Mol Genet 5(Spec No), 
1411–1416 (1996).
 3. Bittles, A. H. & Glasson, E. J. Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev Med 
Child Neurol 46, 282–286 (2004).
 4. Natoli, J. L., Ackerman, D. L., McDermott, S. & Edwards, J. G. Prenatal diagnosis of Down syndrome: a systematic review of 
termination rates (1995–2011). Prenat Diagn 32, 142–153, https://doi.org/10.1002/pd.2910 (2012).
 5. Ivan, D. L. & Cromwell, P. Clinical practice guidelines for management of children with Down syndrome: Part I. J Pediatr Health 
Care 28, 105–110, https://doi.org/10.1016/j.pedhc.2013.05.002 (2014).
17Scientific RepoRts |          (2019) 9:7322  | https://doi.org/10.1038/s41598-019-43820-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
 6. Letourneau, A. et al. Domains of genome-wide gene expression dysregulation in Down’s syndrome. Nature 508, 345–350, https://
doi.org/10.1038/nature13200 (2014).
 7. Lejeune, J. T. R. G. M., Turpin, R. & Gautier, M. Le mongolisme, premier exemple d’aberration autosomique humaine. Ann Genet 
1, 1–49 (1959).
 8. Kahlem, P. Gene-dosage effect on chromosome 21 transcriptome in trisomy 21: implication in Down syndrome cognitive 
disorders. Behav Genet 36, 416–428, https://doi.org/10.1007/s10519-006-9053-z (2006).
 9. Nusse, R. & Varmus, H. Three decades of Wnts: a personal perspective on how a scientific field developed. The EMBO journal 31, 
2670–2684 (2012).
 10. Fuerer, C., Nusse, R. & Ten Berge, D. Wnt signalling in development and disease. Max Delbruck Center for Molecular Medicine 
meeting on Wnt signaling in Development and Disease. EMBO Rep 9, 134–138, https://doi.org/10.1038/sj.embor.7401159 (2008).
 11. Inestrosa, N. C. & Varela-Nallar, L. Wnt signalling in neuronal differentiation and development. Cell Tissue Res 359, 215–223, 
https://doi.org/10.1007/s00441-014-1996-4 (2015).
 12. Inestrosa, N. C. & Arenas, E. Emerging roles of Wnts in the adult nervous system. Nature Rev Neurosci 11, 77–86, https://doi.
org/10.1038/nrn2755 (2010).
 13. Cordero, J. B. & Sansom, O. J. Wnt signalling and its role in stem cell-driven intestinal regeneration and hyperplasia. Acta Physiol 
(Oxf) 204, 137–143, https://doi.org/10.1111/j.1748-1716.2011.02288.x (2012).
 14. Anastas, J. N. & Moon, R. T. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13, 11–26, https://doi.
org/10.1038/nrc3419 (2013).
 15. Wisniewski, K. E., Wisniewski, H. M. & Wen, G. Y. Occurrence of neuropathological changes and dementia of Alzheimer’s disease 
in Down’s syndrome. Ann Neurol 17, 278–282 (1985).
 16. Leverenz, J. B. & Raskind, M. A. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a 
regional quantitative analysis. Exp neurol 150, 296–304 (1998).
 17. Wiseman, F. K. et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci 16, 
564–574, https://doi.org/10.1038/nrn3983 (2015).
 18. Toledo, E. M. & Inestrosa, N. C. Wnt signaling activation reduces neuropathological markers in a mouse model of Alzheimer’s 
disease. Mol Psychiatry 15, 228 (2010).
 19. Inestrosa, N. C., Montecinos-Oliva, C. & Fuenzalida, M. Wnt signaling: role in Alzheimer disease and schizophrenia. J 
Neuroimmune Pharmacol 7, 788–807, https://doi.org/10.1007/s11481-012-9417-5 (2012).
 20. Purro, S. A., Dickins, E. M. & Salinas, P. C. The secreted Wnt antagonist Dickkopf-1 is required for amyloid β-mediated synaptic 
loss. J Neurosci 32, 3492–3498 (2012).
 21. Skaper, S. D. Wnt-signalling: A new direction for alzheimer disease? CNS Neurol Disord Drug Targets 13, 556 (2014).
 22. Tiwari, S. K. et al. Ethosuximide Induces Hippocampal Neurogenesis and Reverses Cognitive Deficits in an Amyloid-beta Toxin-
induced Alzheimer Rat Model via the Phosphatidylinositol 3-Kinase (PI3K)/Akt/Wnt/beta-Catenin Pathway. J Biol Chem 290, 
28540–28558, https://doi.org/10.1074/jbc.M115.652586 (2015).
 23. Kim, D. Y., Jung, S. Y., Kim, K. & Kim, C. J. Treadmill exercise ameliorates Alzheimer disease-associated memory loss through the 
Wnt signaling pathway in the streptozotocin-induced diabetic rats. J Exerc Rehabil 12, 276–283, https://doi.org/10.12965/
jer.1632678.339 (2016).
 24. Vallee, A. & Lecarpentier, Y. Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha 
and Gamma. Front Neurosci 10, 459, https://doi.org/10.3389/fnins.2016.00459 (2016).
 25. Arron, J. R. et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441, 595–600, 
https://doi.org/10.1038/nature04678 (2006).
 26. Fernandez-Martinez, J. et al. Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A. J Cell Sci 122, 
1574–1583, https://doi.org/10.1242/jcs.044354 (2009).
 27. Park, J., Song, W. J. & Chung, K. C. Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell Mol Life Sci 
66, 3235–3240 (2009).
 28. Scales, T. M., Lin, S., Kraus, M., Goold, R. G. & Gordon-Weeks, P. R. Nonprimed and DYRK1A-primed GSK3 beta-phosphorylation 
sites on MAP1B regulate microtubule dynamics in growing axons. J Cell Sci 122, 2424–2435, https://doi.org/10.1242/jcs.040162 
(2009).
 29. Becker, W. Recent insights into the function of DYRK1A. FEBS J 278, 222–222, https://doi.org/10.1111/j.1742-4658.2010.07953.x 
(2011).
 30. Hammerle, B. et al. Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by 
inducing p27(KIP1) expression and suppressing NOTCH signaling. Development 138, 2543–2554, https://doi.org/10.1242/
dev.066167 (2011).
 31. Hong, J. Y. et al. Down’s-syndrome-related kinase Dyrk1A modulates the p120-catenin/Kaiso trajectory of the Wnt signaling 
pathway. J cell sci 125, 561–569 (2012).
 32. Tlili, A. et al. Hepatocyte-specific Dyrk1a gene transfer rescues plasma apolipoprotein A-I levels and aortic Akt/GSK3 pathways in 
hyperhomocysteinemic mice. Biochim Biophys Acta 1832, 718–728, https://doi.org/10.1016/j.bbadis.2013.02.008 (2013).
 33. Booiman, T., Loukachov, V. V., van Dort, K. A., van ‘t Wout, A. B. & Kootstra, N. A. DYRK1A Controls HIV-1 Replication at a 
Transcriptional Level in an NFAT Dependent Manner. PLoS One 10, e0144229, https://doi.org/10.1371/journal.pone.0144229 
(2015).
 34. Najas, S. et al. DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in 
Down Syndrome. EBioMedicine 2, 120–134, https://doi.org/10.1016/j.ebiom.2015.01.010 (2015).
 35. Song, W.-J. et al. Phosphorylation and inactivation of glycogen synthase kinase 3β (GSK3β) by dual-specificity tyrosine 
phosphorylation-regulated kinase 1A (Dyrk1A). J Biol Chem 290, 2321–2333 (2015).
 36. Oi, A. et al. Subcellular distribution of cyclin-dependent kinase-like 5 (CDKL5) is regulated through phosphorylation by dual 
specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). Biochem Biophys Res Commun 482, 239–245, https://doi.
org/10.1016/j.bbrc.2016.11.048 (2017).
 37. Kimura, R. et al. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between β-amyloid 
production and tau phosphorylation in Alzheimer disease. Hum mol gen 16, 15–23 (2007).
 38. Park, J., Yang, E. J., Yoon, J. H. & Chung, K. C. Dyrk1A overexpression in immortalized hippocampal cells produces the 
neuropathological features of Down syndrome. Mol Cell Neurosci 36, 270–279, https://doi.org/10.1016/j.mcn.2007.07.007 (2007).
 39. Ryoo, S. R. et al. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer 
disease. J Biol Chem 282, 34850–34857, https://doi.org/10.1074/jbc.M707358200 (2007).
 40. Ryoo, S. R. et al. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid 
precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease. J Neurochem 104, 1333–1344, 
https://doi.org/10.1111/j.1471-4159.2007.05075.x (2008).
 41. Shi, J. et al. Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down 
syndrome. J Biol Chem 283, 28660–28669, https://doi.org/10.1074/jbc.M802645200 (2008).
 42. Ryu, Y. S. et al. Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer’s 
disease. J Neurochem 115, 574–584 (2010).
1 8Scientific RepoRts |          (2019) 9:7322  | https://doi.org/10.1038/s41598-019-43820-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
 43. Wegiel, J. et al. Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 
3-Repeat Tau Protein in Down Syndrome. J Neuropathol Exp Neurol 70, 36–50, https://doi.org/10.1097/NEN.0b013e318202bfa1 
(2011).
 44. Janel, N. et al. Plasma DYRK1A as a novel risk factor for Alzheimer’s disease. Transl Psychiatry 4, https://doi.org/10.1038/tp.2014.61 
(2014).
 45. Coutadeur, S. et al. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment 
of Alzheimer’s disease: effect on Tau and amyloid pathologies in vitro. J Neurochem 133, 440–451, https://doi.org/10.1111/
jnc.13018 (2015).
 46. Berwick, D. C. et al. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of beta-
catenin signaling. Mol Neurodegener 12, 9, https://doi.org/10.1186/s13024-017-0153-4 (2017).
 47. O’Doherty, A. et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 309, 
2033–2037 (2005).
 48. Gribble, S. M. et al. Massively parallel sequencing reveals the complex structure of an irradiated human chromosome on a mouse 
background in the Tc1 model of Down syndrome. PLoS One 8, e60482, https://doi.org/10.1371/journal.pone.0060482 (2013).
 49. Lana-Elola, E. et al. Genetic dissection of Down syndrome-associated congenital heart defects using a new mouse mapping panel. 
Elife 5, https://doi.org/10.7554/eLife.11614 (2016).
 50. Choong, X. Y., Tosh, J. L., Pulford, L. J. & Fisher, E. Dissecting Alzheimer disease in Down syndrome using mouse models. Front 
Behav Neurosci 9 (2015).
 51. Kramer, A., Green, J., Pollard, J. Jr. & Tugendreich, S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 
523–530, https://doi.org/10.1093/bioinformatics/btt703 (2014).
 52. Sheppard, O. et al. Altered regulation of tau phosphorylation in a mouse model of down syndrome aging. Neurobiol Aging 33, 
https://doi.org/10.1016/j.neurobiolaging.2011.06.025 (2012).
 53. Ahmed, M. M. et al. Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain. Hum Mol 
Genet 22, 1709–1724, https://doi.org/10.1093/hmg/ddt017 (2013).
 54. Yu, T. et al. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum mol gen 179 (2010).
 55. Malliri, A. et al. The rac activator Tiam1 is a Wnt-responsive gene that modifies intestinal tumor development. J Biol Chem 281, 
543–548 (2006).
 56. Koh, S. H. et al. Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 
mouse model of ALS. Exp Neurol 205, 336–346, https://doi.org/10.1016/j.expneurol.2007.03.004 (2007).
 57. Zhou, F. et al. The APP intracellular domain (AICD) inhibits Wnt signalling and promotes neurite outgrowth. Biochim Biophys 
Acta 1823, 1233–1241 (2012).
 58. Szklarczyk, D. et al. String v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43, 
D447–452, https://doi.org/10.1093/nar/gku1003 (2015).
 59. Álvarez, M., Estivill, X. & de la Luna, S. DYRK1A accumulates in splicing speckles through a novel targeting signal and induces 
speckle disassembly. J cell sci 116, 3099–3107 (2003).
 60. Torre, R. et al. Epigallocatechin‐3‐gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in 
humans. Mol Nutr Food Res 58, 278–288 (2014).
 61. Ogawa, Y. et al. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat Commun 1, 86, 
https://doi.org/10.1038/ncomms1090 (2010).
 62. Adayev, T., Wegiel, J. & Hwang, Y.-W. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-
regulated kinase 1A (Dyrk1A). Arch Biochem Biophys 507, 212–218 (2011).
 63. Contestabile, A. et al. Lithium rescues synaptic plasticity and memory in Down syndrome mice. J Clin Invest 123, 348–361, https://
doi.org/10.1172/JCI64650 (2013).
 64. Hammerle, B. et al. Expression patterns and subcellular localization of the Down syndrome candidate protein MNB/DYRK1A 
suggest a role in late neuronal differentiation. Eur J Neurosci 17, 2277–2286 (2003).
 65. Hammerle, B., Elizalde, C. & Tejedor, F. J. The spatio-temporal and subcellular expression of the candidate Down syndrome gene 
Mnb/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development. Eur J Neurosci 27, 
1061–1074, https://doi.org/10.1111/j.1460-9568.2008.06092.x (2008).
 66. Schwarz-Romond, T., Merrifield, C., Nichols, B. J. & Bienz, M. The Wnt signalling effector Dishevelled forms dynamic protein 
assemblies rather than stable associations with cytoplasmic vesicles. J cell sci 118, 5269–5277 (2005).
 67. Sear, R. P. Dishevelled: a protein that functions in living cells by phase separating. Soft Matter 3, 680–684 (2007).
 68. Rachidi, M. & Lopes, C. Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of 
dysregulation in critical chromosome 21 genes and associated molecular pathways. Eur J Paediatr Neurol 12, 168–182, https://doi.
org/10.1016/j.ejpn.2007.08.010 (2008).
 69. Antonarakis, S. E. Down syndrome and the complexity of genome dosage imbalance. Nat Rev Genet 18, 147–163, https://doi.
org/10.1038/nrg.2016.154 (2017).
 70. Olmos-Serrano, J. L. et al. Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte 
Differentiation and Myelination. Neuron 89, 1208–1222, https://doi.org/10.1016/j.neuron.2016.01.042 (2016).
 71. Sullivan, K. D. et al. Trisomy 21 consistently activates the interferon response. Elife 5, https://doi.org/10.7554/eLife.16220 (2016).
 72. Diep, D. B., Hoen, N., Backman, M., Machon, O. & Krauss, S. Characterisation of the Wnt antagonists and their response to 
conditionally activated Wnt signalling in the developing mouse forebrain. Dev Brain Res 153, 261–270, https://doi.org/10.1016/j.
devbrainres.2004.09.008 (2004).
 73. Zenzmaier, C., Marksteiner, J., Kiefer, A., Berger, P. & Humpel, C. Dkk3 is elevated in CSF and plasma of Alzheimer’s disease 
patients. J Neurochem 110, 653–661 (2009).
 74. Reya, T. & Clevers, H. Wnt signalling in stem cells and cancer. Nature 434, 843–850, https://doi.org/10.1038/nature03319 (2005).
 75. McNeill, H. & Woodgett, J. R. When pathways collide: collaboration and connivance among signalling proteins in development. 
Nat Rev Mol Cell Biol 11, 404–413, https://doi.org/10.1038/nrm2902 (2010).
 76. Woods, Y. L. et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the 
microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem. J 
355, 609–615 (2001).
 77. Arron, J. R. et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441, 595–600 
(2006).
 78. Kurabayashi, N., Hirota, T., Sakai, M., Sanada, K. & Fukada, Y. DYRK1A and glycogen synthase kinase 3β, a dual-kinase 
mechanism directing proteasomal degradation of CRY2 for circadian timekeeping. Mol Cell Biol 30, 1757–1768 (2010).
 79. Shen, W. et al. Inhibition of DYRK1A and GSK3B induces human beta-cell proliferation. Nat Commun 6, 8372, https://doi.
org/10.1038/ncomms9372 (2015).
 80. Leonard, J. L. et al. The Dkk3 gene encodes a vital intracellular regulator of cell proliferation. PLoS One 12, e0181724, https://doi.
org/10.1371/journal.pone.0181724 (2017).
 81. Caricasole, A. et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration 
in Alzheimer’s brain. J Neurosci 24, 6021–6027 (2004).
1 9Scientific RepoRts |          (2019) 9:7322  | https://doi.org/10.1038/s41598-019-43820-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
 82. Purro, S. A., Galli, S. & Salinas, P. C. Dysfunction of Wnt signaling and synaptic disassembly in neurodegenerative diseases. Journal 
of molecular cell biology, mjt0 49 (2014).
 83. Lie, D. C. et al. Wnt signalling regulates adult hippocampal neurogenesis. Nature 437, 1370–1375, https://doi.org/10.1038/
nature04108 (2005).
 84. Seib, D. R. et al. Loss of Dickkopf-1 restores neurogenesis in old age and counteracts cognitive decline. Cell Stem Cell 12, 204–214 
(2013).
 85. Chen, J., Park, C. S. & Tang, S. J. Activity-dependent synaptic Wnt release regulates hippocampal long term potentiation. J Biol 
Chem 281, 11910–11916, https://doi.org/10.1074/jbc.M511920200 (2006).
 86. Stewart, D. J. Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 106, djt356, https://doi.org/10.1093/jnci/
djt356 (2014).
 87. Sullivan, S. G., Hussain, R., Glasson, E. J. & Bittles, A. H. The profile and incidence of cancer in Down syndrome. J Intellect Disabil 
Res 51, 228–231, https://doi.org/10.1111/j.1365-2788.2006.00862.x (2007).
 88. Malinge, S. et al. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine 
model of Down syndrome. The Journal of clinical investigation 122, 948–962 (2012).
 89. Xue, G., Romano, E., Massi, D. & Mandala, M. Wnt/beta-catenin signaling in melanoma: Preclinical rationale and novel therapeutic 
insights. Cancer Treat Rev 49, 1–12, https://doi.org/10.1016/j.ctrv.2016.06.009 (2016).
 90. Yang, K. et al. The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer 
therapies. Lab Invest 96, 116–136, https://doi.org/10.1038/labinvest.2015.144 (2016).
 91. Harvey, K. & Marchetti, B. Regulating Wnt signaling: a strategy to prevent neurodegeneration and induce regeneration. J Mol Cell 
Biol 6, 1–2, https://doi.org/10.1093/jmcb/mju002 (2014).
 92. Wan, W., Xia, S., Kalionis, B., Liu, L. & Li, Y. The role of Wnt signaling in the development of Alzheimer’s disease: a potential 
therapeutic target? Biomed Res Int 2014, 301575, https://doi.org/10.1155/2014/301575 (2014).
 93. Becker, W., Soppa, U. & Tejedor, F. J. DYRK1A: a potential drug target for multiple Down syndrome neuropathologies. CNS Neurol 
Disord Drug Targets 13, 26–33 (2014).
 94. Stagni, F. et al. Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome? Neurogenesis (Austin) 4, 
e1270383, https://doi.org/10.1080/23262133.2016.1270383 (2017).
 95. Sancho, R. M., Law, B. M. & Harvey, K. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson’s disease to Wnt 
signalling pathways. Hum Mol Genet 18, 3955–3968, https://doi.org/10.1093/hmg/ddp337 (2009).
 96. Veeman, M. T., Slusarski, D. C., Kaykas, A., Louie, S. H. & Moon, R. T. Zebrafish prickle, a modulator of noncanonical Wnt/Fz 
signaling, regulates gastrulation movements. Curr Biol 13, 680–685 (2003).
 97. Nixon-Abell, J. et al. Protective LRRK2 R1398H variant enhances GTPase and Wnt signaling activity. Front Mol Neurosci 9 (2016).
 98. Vojtek, A. B. & Hollenberg, S. M. Ras-Raf interaction: two-hybrid analysis. Methods Enzymol 255, 331–342 (1995).
 99. Bartel, P., Chien, C. T., Sternglanz, R. & Fields, S. Elimination of false positives that arise in using the two-hybrid system. 
Biotechniques 14, 920–924 (1993).
 100. Fromont-Racine, M., Rain, J. C. & Legrain, P. Toward a functional analysis of the yeast genome through exhaustive two-hybrid 
screens. Nat Genet 16, 277–282, https://doi.org/10.1038/ng0797-277 (1997).
 101. Rain, J. C. et al. The protein-protein interaction map of Helicobacter pylori. Nature 409, 211–215, https://doi.org/10.1038/35051615 
(2001).
Acknowledgements
We are grateful to the Jerome LeJeune foundation (Paris, France) and Hybrigenics services for access to the 
InterPP project database (https://www.fondationlejeune.org/en/our-missions-and-actions/research/research-
programme/). We thank Dr. Jean-Maurice Delabar (French National Centre for Scientific Research, Paris, France) 
for mediating the collaboration with the Jerome LeJeune foundation. We thank Nneka Anyanwu (Francis Crick 
Institute, London, UK) for the kind help with IPA analysis. We also thank Oke Avwenagha (UCL Institute of 
Neurology, London, UK) for providing access to postmortem human samples. This work was supported by SG’s 
UCL Impact PhD studentship to K.H. and E.M.C.F., the MRC grant MR/M00676X/1 to K.H., the Wellcome 
Trust grant WT095010MA to K.H. V.L.J.T. and E.M.C.F. were funded by Wellcome Trust grants 080174, 098327 
and 098328, and by the AnEUploidy integrated project (EU Framework 6). F.K.W., V.L.J.T., E.M.C.F. are funded 
by a Wellcome Trust Strategic Award (098330/Z/12/Z) awarded to The London Down Syndrome (LonDownS) 
Consortium; V.L.J.T. and E.M.C.F. are funded by a Wellcome Trust Joint Senior Investigators Award and by the 
Medical Research Council (U117527252; awarded to V.L.J.T. and G0601056 awarded to V.L.J.T. and E.M.C.F.), 
as well as by awards from Alzheimer’s Research UK (F.K.W., E.M.C.F.), Alzheimer’s Society (F.K.W., E.M.C.F.); 
V.L.J.T. was also funded by the Francis Crick Institute which receives its core funding from the UK Medical 
Research Council (FC001194), Cancer Research UK (FC001194) and the Wellcome Trust (FC001194). J.T. was 
funded by an Alzheimer’s Society studentship awarded to E.M.C.F. and F.W.
Author Contributions
S.G., D.C.B., F.K.W. and K.H. conceived and designed the majority of experiments. S.G. performed majority 
of experiments. S.G. and K.H. analysed majority of the data and wrote the manuscript. J.N.A. designed and 
performed imaging experiments and analysed the data. J.T., M.Z., V.P. and F.K.W. designed and performed 
RNAseq experiments and analysed the data. G.H., S.A. and Z.N. performed experiments and analysed the data. 
S.G. and K.C. performed human sample experiments and S.G. analysed the data. J.C.R. designed and performed 
Y2H experiments and analysed the data. V.L.J.T. and E.M.C.F. developed the Tc1 mouse model. S.G., D.C.B., 
E.M.C.F. and K.H. edited the first draft of the manuscript; all authors read and approved the final version.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-43820-4.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
20Scientific RepoRts |          (2019) 9:7322  | https://doi.org/10.1038/s41598-019-43820-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
